These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 3514325)

  • 1. Persistence of polymicrobial abscesses in the poorly controlled diabetic host.
    Bessman AN; Sapico FL; Tabatabai M; Montgomerie JZ
    Diabetes; 1986 Apr; 35(4):448-53. PubMed ID: 3514325
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo pH of induced soft-tissue abscesses in diabetic and nondiabetic mice.
    Bessman AN; Page J; Thomas LJ
    Diabetes; 1989 May; 38(5):659-62. PubMed ID: 2714521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reciprocal synergy between Escherichia coli and Bacteroides fragilis in an intra-abdominal infection model.
    Rotstein OD; Kao J; Houston K
    J Med Microbiol; 1989 Aug; 29(4):269-76. PubMed ID: 2668529
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergy in polymicrobial infections in a mouse model of type 2 diabetes.
    Mastropaolo MD; Evans NP; Byrnes MK; Stevens AM; Robertson JL; Melville SB
    Infect Immun; 2005 Sep; 73(9):6055-63. PubMed ID: 16113326
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of anaerobic bacteria in intra-abdominal septic abscesses in mediating septic control of skeletal muscle glucose oxidation and lactic acidemia.
    Vary TC; Siegel JH; Tall B; Morris JG
    J Trauma; 1989 Jul; 29(7):1003-13; discussion 1013-4. PubMed ID: 2664200
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo efficacy of trovafloxacin against Bacteroides fragilis in mixed infection with either Escherichia coli or a vancomycin-resistant strain of Enterococcus faecium in an established-abscess murine model.
    Stearne LE; Gyssens IC; Goessens WH; Mouton JW; Oyen WJ; van der Meer JW; Verbrugh HA
    Antimicrob Agents Chemother; 2001 May; 45(5):1394-401. PubMed ID: 11302801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In-vivo bactericidal activity of Sch 34343 in Bacteroides fragilis abscesses and in Bacteroides fragilis-Escherichia coli abscesses.
    Wells CL; Arland LA; Simmons RL; Rotstein OD
    J Antimicrob Chemother; 1985 Jun; 15 Suppl C():199-206. PubMed ID: 3897172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The spectrum of Escherichia coli--Bacteroides fragilis pathogenic synergy in an intraabdominal infection model.
    Rotstein OD; Kao J
    Can J Microbiol; 1988 Mar; 34(3):352-7. PubMed ID: 3046726
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo efficacies of quinolones and clindamycin for treatment of infections with Bacteroides fragilis and/or Escherichia coli in mice: correlation with in vitro susceptibilities.
    Brook I
    Antimicrob Agents Chemother; 1993 May; 37(5):997-1000. PubMed ID: 8517727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The treatment of irradiated mice with polymicrobial infection caused by Bacteroides fragilis and Escherichia coli.
    Brook I; Ledney GD
    J Antimicrob Chemother; 1994 Feb; 33(2):243-52. PubMed ID: 8182005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro susceptibility and in vivo efficacy of antimicrobials in the treatment of Bacteroides fragilis-Escherichia coli infection in mice.
    Brook I
    J Infect Dis; 1989 Oct; 160(4):651-6. PubMed ID: 2677161
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathogenicity of capsulate and non-capsulate members of Bacteroides fragilis and B. melaninogenicus groups in mixed infection with Escherichia coli and Streptococcus pyogenes.
    Brook I
    J Med Microbiol; 1988 Nov; 27(3):191-8. PubMed ID: 2903934
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intestinal bacteria translocate into experimental intra-abdominal abscesses.
    Wells CL; Rotstein OD; Pruett TL; Simmons RL
    Arch Surg; 1986 Jan; 121(1):102-7. PubMed ID: 3510604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergy of Bacteroides fragilis and Escherichia coli in the induction of KC gene expression in mouse peritoneal tissues.
    Kim JM; Kim YJ; Cho YJ
    Scand J Infect Dis; 2000; 32(6):643-9. PubMed ID: 11200375
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of metronidazole on Escherichia coli in the presence of Bacteroides fragilis: an investigation in mice.
    Reznikov M; McDonald PJ
    Chemotherapy; 1983; 29(3):225-9. PubMed ID: 6347547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Susceptibility of the liver and biliary tract to anaerobic infection in extrahepatic biliary tract obstruction. III. Possible synergistic effect between anaerobic and aerobic bacteria. An experimental study in rabbits.
    Lykkegaard Nielsen M; Asnaes S; Justesen T
    Scand J Gastroenterol; 1976; 11(3):263-72. PubMed ID: 775613
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathogenicity of enterococci in a rat model of fecal peritonitis.
    Matlow AG; Bohnen JM; Nohr C; Christou N; Meakins J
    J Infect Dis; 1989 Jul; 160(1):142-5. PubMed ID: 2543707
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early events after intra-abdominal infection with Bacteroides fragilis and Escherichia coli.
    Verweij WR; Namavar F; Schouten WF; MacLaren DM
    J Med Microbiol; 1991 Jul; 35(1):18-22. PubMed ID: 2072375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fibrin in peritonitis. IV. Synergistic intraperitoneal infection caused by Escherichia coli and Bacteroides fragilis within fibrin clots.
    Dunn DL; Rotstein OD; Simmons RL
    Arch Surg; 1984 Feb; 119(2):139-44. PubMed ID: 6365029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic efficacy and pharmacokinetic properties of ciprofloxacin in intra-abdominal abscesses caused by Bacteroides fragilis and Escherichia coli.
    Fu KP; Vince T; Bloom R; Gregory FJ; Hung PP
    Drugs Exp Clin Res; 1987; 13(8):493-6. PubMed ID: 3322752
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.